-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 2, Haisco issued an announcement stating that its wholly-owned subsidiary, Liaoning Haisco Pharmaceuticals, had recently obtained the "Notice of Drug Clinical Trial Approval" issued by the Drug Evaluation Center of the State Drug Administration
According to the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the HSK21542 injection accepted on May 12, 2021 meets the relevant requirements of drug registration, and it is agreed to carry out the phase II clinical trial of "liver disease itching"
HSK21542 has completed two phase I clinical trials in healthy people, and other INDs that have been applied for include two indications: acute and chronic pain (Phase Ⅲ in progress) and pruritus indication (Phase Ⅱ in progress)